文献速递妇科产科

中年过渡期与心血管疾病及癌症风险 第一部分:程度与机制

The midlife transition and the risk of cardiovascular disease and cancer Part I: magnitude and mechanisms.
PubMed 文献 · Am J Obstet Gynecol · 2020-06-01

心脏病和癌症是美国主要死因,女性冠心病及乳腺癌、子宫内膜癌、卵巢癌在绝经过渡期数十年间临床显现并加速。本文为两部分专家综述的第一部分,界定妇科医生在中年(主要为绝经后)患者照护中面临各项临床挑战的维度、严重程度及交互协同作用,描述可临床识别、潜在可治疗的致病机制。

要点

  • 心脏病和癌症是美国主要死因,女性冠心病及乳腺癌、子宫内膜癌、卵巢癌在绝经过渡期加速显现。
  • 40至65岁间代谢综合征组分(内脏肥胖、高血压、糖尿病、血脂异常)出现并加速。
  • 子宫内膜癌与代谢综合征存在交互作用,两项临床报告提供统计学支持。

核心结论

  • 心脏病和癌症是美国主要死因,女性冠心病及乳腺癌、子宫内膜癌、卵巢癌在绝经过渡期数十年间临床显现并加速。
  • 子宫内膜癌与代谢综合征存在阳性交互作用,无论有无内脏肥胖。
  • 两个关键临床问题需分析回答:为何绝经后慢性病及雌激素受体丰富肿瘤发病率加速而雌激素治疗刺激其出现;识别病因驱动因素应在多大程度上修改妇科医生职责。

研究设计与样本

  • 本文为两部分专家综述的第一部分,界定妇科医生照护中年(主要为绝经后)患者时面临各项临床挑战的维度、严重程度及交互协同作用。
  • 第二部分(已被《美国妇产科杂志》接受)确定成功临床照护的7个目标,提供分诊优先靶点及初级预防措施插入机会,并描述重新规划的门诊访视。

主要发现

  • 40至65岁间代谢综合征组分出现并加速,包括内脏肥胖(以腰围测量)、高血压、糖尿病和血脂异常。
  • 骨质疏松、骨关节炎、肌少症、抑郁甚至认知下降和痴呆出现,多数被认为功能相关。
  • 一项报告描述在老年及代谢易感人群的大型择期子宫切除术系列中发现未疑及子宫内膜癌。
  • 另一项来自妇女健康倡议观察研究,发现子宫内膜癌与代谢综合征间阳性交互作用,无论有无内脏肥胖。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heart disease and cancer are the leading causes of death in the United States. In women, the clinical appearance of both entities-coronary heart disease and cancer (breast, endometrium, and ovary)-escalate during the decades of the midlife transition encompassing the menopause. In addition to the impact of aging, during the interval between the age of 40 and 65 years, the pathophysiologic components of metabolic syndrome also emerge and accelerate. These include visceral adiposity (measured as waist circumference), hypertension, diabetes, and dyslipidemia. Osteoporosis, osteoarthritis, sarcopenia, depression, and even cognitive decline and dementia appear, and most, if not all, are considered functionally related. Two clinical reports confirm the interaction linking the emergence of disease: endometrial cancer and metabolic syndrome. One describes the discovery of unsuspected endometrial cancer in a large series of elective hysterectomies performed in aged and metabolically susceptible populations. The other is from the Women's Health Initiative Observational Study, which found a positive interaction between endometrial cancer and metabolic syndrome regardless of the presence or absence of visceral adiposity. Both provide additional statistical support for the long-suspected causal interaction among the parallel but variable occurrence of these common entities-visceral obesity, heart disease, diabetes, cancer, and the prevalence of metabolic syndrome. Therefore, 2 critical clinical questions require analysis and answers: 1: Why do chronic diseases of adulthood-metabolic, cardiovascular, endocrine-and, in women, cancers of the breast and endometrium (tissues and tumors replete with estrogen receptors) emerge and their incidence trajectories accelerate during the postmenopausal period when little or no endogenous estradiol is available, and yet the therapeutic application of estrogen stimulates their appearance? 2: To what extent should identification of these etiologic driving forces require modification of the gynecologist's responsibilities in the care of our patients in the postreproductive decades of the female life cycle? Part l of this 2-part set of "expert reviews" defines the dimensions, gravity, and interactive synergy of each clinical challenge gynecologists face while caring for their midlife (primarily postmenopausal) patients. It describes the clinically identifiable, potentially treatable, pathogenic mechanisms driving these threats to quality of life and longevity. Part 2 (accepted, American Journal of Obstetrics & Gynecology) identifies 7 objectives of successful clinical care, offers "triage" prioritization targets, and provides feasible opportunities for insertion of primary preventive care initiatives. To implement these goals, a reprogrammed, repurposed office visit is described.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Kase NG, Gretz Friedman E, Brodman M, et al. The midlife transition and the risk of cardiovascular disease and cancer Part I: magnitude and mechanisms. Am J Obstet Gynecol. 2020. PMID: 32497614. doi:10.1016/j.ajog.2020.05.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。